Equities analysts at house broker finnCap reiterated their 15p target share price for Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) against the AIM-quoted life sciences company’s latest market price of 8.8p.
During a capital markets day held on Wednesday 30 November 2022, Poolbeg stressed its capabilities in the discovery and development of anti-viral drugs and anti-bacterial vaccines, as well as its proprietary patient datasets that aid these drug discovery programmes and wider business-development strategy.
Poolbeg reiterated its plans to monetise assets sooner rather than later, with potential partnering deals from 2023 without having to raise more funds through the market.
“With multiple potential sources of news flow due over the coming months… there are several events that could be catalysts for the shares,” noted Jonathan Wright at finnCap.